Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Dow
Baxter
Harvard Business School

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

MAVENCLAD Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Mavenclad, and when can generic versions of Mavenclad launch?

Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-five patent family members in thirty-three countries.

The generic ingredient in MAVENCLAD is cladribine. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cladribine profile page.

Drug patent expirations by year for MAVENCLAD
Drug Prices for MAVENCLAD

See drug prices for MAVENCLAD

Recent Clinical Trials for MAVENCLAD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sykehuset TelemarkPhase 3
Helse Stavanger HFPhase 3
Vestre Viken Hospital TrustPhase 3

See all MAVENCLAD clinical trials

Pharmacology for MAVENCLAD
Synonyms for MAVENCLAD
(2R,3S,5R)-5-(6-amino-2-chloro-9-purinyl)-2-(hydroxymethyl)-3-oxolanol
(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2R,3S,5R)-5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxalan-3-ol
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-azanyl-2-chloranyl-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
2-CdA
2-chloro-2'-deoxy-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxyadenosine
2-Chloro-2'-deoxyadenosine, antileukemic
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-chloro-deoxyadenosine
2-Chlorodeoxyadenosine
291C638
2CdA
2ClAdo
4291-63-8
47M74X9YT5
6-amino-2-chloro-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
6-amino-2-chloro-9-(2-deoxy-beta-erythropentofuranosyl)purine
A826062
AB0011806
AB00382963_19
AB00382963-17
AC-7591
AC1L2FXP
ACT02615
Adenosine, 2-chloro-2'-deoxy
ADENOSINE, 2-CHLORO-2'-DEOXY-
AJ-45639
AK-46529
AKOS015854898
AKOS015892544
AS-12366
AX8000129
BCP02868
BCP9000538
BDBM38920
BR-46529
BRN 0624220
C-17986
C10H12ClN5O3.C3H8
CAS-4291-63-8
CC-25898
CC0168
CCG-101116
CCRIS 9374
CHEBI:567361
CHEMBL1619
Chlorodeoxyadenosine
cid_20279
CJ-10765
CL9
Cladarabine
Cladaribine
Cladiribine
cladribina
Cladribine
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
Cladribine [USAN:USP:INN:BAN]
Cladribine for peak identification, European Pharmacopoeia (EP) Reference Standard
Cladribine, European Pharmacopoeia (EP) Reference Standard
Cladribine, United States Pharmacopeia (USP) Reference Standard
cladribinum
CldAdo
CPD000058553
CS-2057
CTK8D4033
D01370
DB00242
DSSTox_CID_2828
DSSTox_GSID_22828
DSSTox_RID_76747
DTXSID8022828
FT-0080707
GTPL4799
HMS2052K13
HMS2232C23
HMS3715F17
HSDB 7564
HY-13599
Leustat
Leustatin
Leustatin (TN)
Leustatin|||2-Chloro-2'-deoxyadenosine|||2-CdA|||NSC-105014-F|||(2R,3S,5R)-5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
Litak
LS-15109
MFCD00153939
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MLS001424194
Movectro
Mylinax
NC00366
NCGC00018167-03
NCGC00022567-05
NCGC00022567-06
NCGC00022567-07
NCGC00022567-08
NCGC00164384-01
NCGC00254518-01
NSC 105014
NSC 105014-F
NSC-105014
Opera_ID_1191
PTOAARAWEBMLNO-KVQBGUIXSA-N
RTC-063884
RWJ 26251
RWJ-26251
RWJ-26251-000
S-7479
S1199
SAM001246526
SC-17356
SCHEMBL3775
SMR000058553
SR-01000003063
SR-01000003063-10
SR-01000003063-7
ST2409775
SW197746-4
TC-063884
Tox21_110834
Tox21_300596
UNII-47M74X9YT5
ZINC3798064

US Patents and Regulatory Information for MAVENCLAD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for MAVENCLAD

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1827461 2018C/010 Belgium   Start Trial PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
1827461 CR 2018 00010 Denmark   Start Trial PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824
2805723 C20180006 00238 Estonia   Start Trial PRODUCT NAME: KLADRIBIIN;REG NO/DATE: EU/1/17/1212 24.08.2017
1608344 PA2018502 Lithuania   Start Trial PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822
1608344 PA2018502,C1608344 Lithuania   Start Trial PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822
1827461 9/2018 Austria   Start Trial PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170824
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Boehringer Ingelheim
Moodys
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.